AAV-monoclonal antibody expression protects mice from Ebola virus without impeding the endogenous antibody response to heterologous challenge

Filoviruses cause severe hemorrhagic fever with case fatality rates as high as 90%. Filovirus-specific monoclonal antibodies (mAbs) confer protection in nonhuman primates as late as 5 days after challenge, and FDA-approved mAbs REGN-EB3 and mAb114 have demonstrated efficacy against Ebola virus (EBOV...

Descripción completa

Detalles Bibliográficos
Autores principales: van Lieshout, Laura P., Rghei, Amira D., Cao, Wenguang, He, Shihua, Soule, Geoff, Zhu, Wenjun, Thomas, Sylvia P., Sorensen, Debra, Frost, Kathy, Tierney, Kevin, Thompson, Brad, Booth, Stephanie, Safronetz, David, Kulkarni, Raveendra R., Bridle, Byram W., Qiu, Xiangguo, Banadyga, Logan, Wootton, Sarah K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9436706/
https://www.ncbi.nlm.nih.gov/pubmed/36092367
http://dx.doi.org/10.1016/j.omtm.2022.08.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9436706/
https://www.ncbi.nlm.nih.gov/pubmed/36092367
http://dx.doi.org/10.1016/j.omtm.2022.08.003

Ejemplares similares